The U.S. Department of Health and Human Services (HHS) Office on Women’s Health announced the 20 winners of Phase I of the HHS Hypertension Innovator Award Competition.  The competition was created to identify effective, pre-existing programs that care for people with hypertension where the programs could be or are already applied to women with hypertension who are pregnant and/or postpartum. The goal of the competition is to demonstrate sustainability and the ability to replicate and/or expand programs that provide effective monitoring and follow-up of hypertension for women who are pregnant and/or postpartum.

Congratulations go to Emagine Solutions Technology and Valleywise (in collaboration with Creighton University).Continue reading→

If understanding the inner workings of the brain is on your mind, now is the time to explore the Banner-ASU Neuroscience Scholars program. Top-achieving college undergraduate and graduate science students are eligible to apply for the paid eight-week training program. Applications must be received by March 1.Continue reading→

The Arizona Biomedical Research Centre is soliciting applications from eligible entities to fill the FY2022 Research Grant Cohort. Letters of Intent for New Investigator Awards (NIA) or Investigator Grants (IG) will be accepted starting Wednesday, January 5, 2022 through 3:00 p.m. MST, January 19, 2022. Instructions and application materials can be found at https://portal.ecivis.com. The solicitation number is RFGA2022-010.Continue reading→

For over 50 years, Novartis has developed innovative medicines to treat cardiovascular disease. Building on this legacy, I am reaching out to share the news that Novartis received approval from the U.S. Food and Drug Administration (FDA) for Leqvio^® (inclisiran), the first and only small interfering RNA (siRNA) to provide effective and sustained reduction in low-density lipid cholesterol (LDL-C), commonly referred to as “bad cholesterol,” as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality has not yet been determined but is being explored in clinical trials currently underway.

The United States spends over $125 billion on direct medical expenses for ASCVD care each year, and heart disease and stroke represent the largest medical expenditures in the country. Beyond direct healthcare costs, heart disease and stroke have been estimated to result in $138 billion annually in lost productivity.

Continue reading→

2021 was a challenging year in many ways.  It was also a year when AZBio Members stepped up to meet these challenges.  As we look forward to 2022, we are focused on AZBio’s vision of Arizona becoming a top-ten bioscience state.  We  invite you to learn more about how you can get engaged with  AZBio in 2022 and participate in focus initiatives designed to move us toward the top-ten. Continue reading→

Cxcl10 protein can indicate both positive and negative directions of cancer trajectoryContinue reading→

Expands Potential Market and Study Opportunities for HTG Transcriptome Panel

Continue reading→

‘Nomograms’ accounting for sex differences in the design of clinical trials should help deliver new precision treatments to glioblastoma patientsContinue reading→

Continue reading→